Qiming Venture Partners USA

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 18
Average round size
info
The average size of a deal this fund participated in
$63M
Portfolio companies 12
Rounds per year 1.20
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.33
Exits 2
Key employees 12
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Medical
Summary

Qiming Venture Partners USA is the famous VC, which was founded in 2006.

The overall number of key employees were 12.

The usual cause for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Surveyor Capital, Sanofi, NanoDimension. In the next rounds fund is usually obtained by Roche Venture Fund.

Among the various public portfolio startups of the fund, we may underline Icosavax Among the most popular fund investment industries, there are Health Care, Biotechnology. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.

The fund is generally included in 2-6 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The high activity for fund was in 2019.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Qiming Venture Partners USA:
Typical Co-investors
Qiming Venture Partners USA is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Qiming Venture Partners USA:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
313 Ventures Detroit, Michigan, United States
Ammann Group Bern, Langenthal, Switzerland
Banque Populaire Atlantique -
Barinboim Investment -
Brazilian Ministry of Health Brasília, Brazil, Rio Grande do Norte
Cherry Creek Holdings -
Cloud Ventures China, Guangdong, Shenzhen
Enlight Ventures -
H20 Capital -
Honeycomb Investment Trust England, London, United Kingdom
KAIST Venture -
Meltwind Advisory Cambridge, Cambridgeshire, United Kingdom
MTGx Stockholm, Stockholm County, Sweden
Neogen.biz -
OneSpan Chicago, Illinois, United States
Prescott General Partners -
Safestone Technologies Ltd England, Sheffield, United Kingdom
Venus MedTech China, Hangzhou, Zhejiang
Xenon Ventures Beaverton, Oregon, United States
YungPark Capital China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Jasper Therapeutics

Biotechnology
Health Care
Pharmaceutical
$100M27 Sep 2021 Latvia, Courland, Latvia

Ventyx Biosciences

Biopharma
Biotechnology
$51M20 Sep 2021 Encinitas, California, United States

Soda Health

Health Care
Medical
$6M19 Aug 2021 -

LetsGetChecked

Health Care
Health Diagnostics
Medical
$150M08 Jun 2021 New York, New York, United States

Ventyx Biosciences

Biopharma
Biotechnology
$114M09 Mar 2021 Encinitas, California, United States

Auron Therapeutics

Biotechnology
Health Care
Therapeutics
$12M28 Jan 2021 Massachusetts, United States

Biotechnology
Pharmaceutical
$53M07 Jan 2021 Hong Kong

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
$65M18 Nov 2020 New York, United States

Talaris Therapeutics

Biotechnology
Health Care
Therapeutics
$115M06 Oct 2020 Massachusetts, United States
News
HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Soda Health Raises $6M in Seed Funding

– Soda Health from Bentonville is a healthcare technology company.
– The company raised $6m in seed funding.
– The round was led by Lightspeed Venture Partners and Define Ventures with participation from Qiming Venture Partners USA.
– The new investment will be used to expand operations and business reach.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Qiming Venture Partners USA?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: